A cluster of medical device stocks saw analyst recommendation changes on Friday. Boston Scientific drew multiple simultaneous rating actions. The consensus average target price dipped slightly to $79.40 from $80.16. Despite the mixed moves, Buy ratings still dominate — 27 analysts remain bullish.
Stryker saw its consensus target price edge down to $389.24 from $389.43. The $118 billion orthopaedics giant holds a strong Buy-leaning consensus. Short interest sits at just 1.8% of free float. That signals little bearish pressure from the market.
Devon Energy was the standout mover outside healthcare. The consensus target lifted to $61.24 from $61.12. The energy producer carries a market cap near $51 billion. All 20 covering analysts hold Buy ratings.
Several medtech names — including Medtronic, Edwards Lifesciences, DexCom, and Zimmer Biomet — saw recommendations removed, trimming analyst counts. This likely reflects post-earnings coverage resets rather than negative sentiment shifts.
Abbott Laboratories and Intuitive Surgical also had recommendations removed. Both retain strong Buy-leaning consensus from remaining coverage. Medtech sector sentiment stays broadly constructive heading into summer.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
